NFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
Use several sheets if necessary)
Sheet 1 of

 COMPLETE IF KNOWN

 Application Number
 10/591,358

 Confirmation Number
 5946

 Fling Date
 August 12, 2008

 First Named Inventor
 Yuan et al.

 Group At Unit
 1625

 Examiner Name
 Chandrakumar, Nizal S.

 Attorney Docket No.
 57070-8021 US00

			U	I.S. PATENT DOCUMENTS		
		U.S. Patent or Application	on		Date of Publication or	Pages, Columns, Lines,
Examiner Initials	Cite No.		d Code known)	Name of Patentee or Inventor of Cited Document	Filing Date of Cited Document	Where Relevant Figures Appear
/N.0	/ 1.	US-2002/0077350	A1	Babish et al.	06-20-2002	
	2.	US-2002/0099051	A1	Fidler et al.	07-25-2002	
	3.	US-2004/0018260	A1	Ren et al.	01-29-2004	
	4.	US-2004/0152767	A1	Dai et al.	08-05-2004	
	5.	US-2004/0198808	A1	Dai et al.	10-07-2004	
	6.	US-2004/0235943	A1	Dai et al.	11-25-2004	
	7.	US-2005/2883645	A1	LaVon	12-29-2005	
	8.	US-2007/0244080	A1	Fidler et al.	10-18-2007	
	9.	US-2007/0249048	A1	Dai et al.	10-25-2007	
	10.	US-2007/0282114	A1	An et al.	12-06-2007	
	11.	US-2008/0287530	A1	Yuan et al.	11-20-2008	
	12.	US-5,192,817		Takaishi et al.	03-09-1993	
	13.	US-5,430,054		Qian et al.	07-04-1995	
	14.	US-5,468,772		Xu et al.	11-21-1995	
	15.	US-5,580,562		Lipsky et al.	12-03-1996	
	16.	US-5,648,376		Strobel et al.	07-15-1997	
	17.	US-5,759,550		Weidmann et al.	06-02-1998	
	18.	US-5,843,452		Weidmann et al.	12-01-1998	
	19.	US-5,919,816		Hausheer et al.	07-06-1999	
	20.	US-6,011,042		Greenwald et al.	01-04-2000	
	21.	US-6,103,875		Martinez-Miller et al.	08-15-2000	
	22.	US-6,294,546	B1	Rosen et al.	09-25-2001	
	23.	US-6,329,148	B1	Rosen et al.	12-11-2001	
	24.	US-6,458,537		Staub et al.	10-01-2002	
	25.	US-6,537,984		Rosen et al.	03-25-2003	
,,	26:	US-6,548,537	B1	Dai et al.	04-15-2003	
<b>W</b> /N.0	<b>)/27</b> .	US-6,599,499		Rosen et al.	07-29-2003	

9

EXAMINER	AT 101 11 1	DATE CONSIDERED		
	/Nizal Chandrakumar/	09/06/2009		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	onformance with MPEP 609. Draw line through citation if not in		

				COMPLETE IF KNOWN		
•				Application Number	10/591,358	
	INFORMATION			Confirmation Number	9546	
	STATEMENT E			Filing Date	August 12, 2008	
	Form PTO-14			First Named Inventor	Yuan et al.	
	(Use several she	ets if necessary	)	Group Art Unit	1625	
				Examiner Name	Chandrakumar, Nizal S.	
Sheet	. 2	of	9	Attomey Docket No.	57070-8021.US00	

						,
	/N.	2/8.	US-6,620,843	B2	Fidler et al.	09-16-2003
		29.	US-6,620,843	B1	Fidler et al.	09-16-2003
		30.	US-6,777,441		Wang et al.	08-17-2004
	-	31.	US-6,943,259	B2	Dai et al.	09-13-2005
		32.	US-7,019,151	B2	Dai et al.	03-28-2006
_	,	33.	US-7,098,348	B2	Dai et al.	08-29-2006
V	/N.C.	34.	US-7,417,069	B2	Dai et al.	08-26-2008

					FORE	GN PATENT DOCUMENTS			
	aminer nitial	Cite No.	Office	oreign Patent or Application	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	Т
	/N	.C.7	CN	CN 1052859	Α	Skin Disease Inst. Chinese Acad. (CN) (English Abstract only)	07-10-1991		1
		36.	CN	CN 1317248	Α	Fujian Province Medical Research Institute (English Translation)	10-17-2001		1
		37.	EPO	EP 0 156 643	B1	The Upjohn Company	10-02-1985		T
_		38.	PCT	WO 94/26265	A1	Pharmagenesis, Inc.	11-24-1994		
		39.	PCT	WO 00/63212		Chengdu Diao Pharmaceutical group Company Limited	10-26-2000		
1		40.	PCT	WO 02/070472	A1	Pharmagenesis, Inc.	09-12-2002		
1		41.	PCT	WO 02/074759	A1	Pharmagenesis, Inc.	09-26-2002		
T		42.	PCT	WO 03/101951	A2	Pharmagenesis Inc.	12-11-2003		
T		43.	PCT	WO 05/000291	A1	Pharmagenesis, Inc.	01-06-2005		
T		44.	PCT	WO 05/020887	A2	Pharmagenesis, Inc.	03-10-2005		
		45.	PCT	WO 05/062913	A2	Pharmagenesis Inc.	07-14-2005		
V	4	46.	PCT	WO 05/084365	A2	Pharmagenesis Inc.	09-15-2005		Ľ
4	/N	<u>c</u> 47.	PCT	WO 06/012204	A2	Pharmagenesis Inc.	02-02-2006		

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009
*EXAMINER:	Initial if reference considered, whether or not criteria is in confermance and not considered. Include conv. of this form	onformance with MPEP 609. Draw line through citation if not in

					COMPLETE IF KNOWN
•				Application Number	10/591,358
	INFORMATION			Confirmation Number	9546
	STATEMENT E			Filing Date	August 12, 2008
	Form PTO-14			First Named Inventor	Yuan et al.
	(Use several she	ets if necessary	)	Group Art Unit	1625
				Examiner Name	Chandrakumar, Nizal S.
Sheet	3	of	9	Attorney Docket No.	57070-8021.US00

OTHER NON PATENT LITERATURE DOCUMENTS

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	т
/N	<b>.48</b> .	AUMULLER, G. et al., "Intermediate filaments in sertoli cells", <i>Microscopy Research</i> and <i>Technique</i> , 20:50-72(1992).	
	49.	BECKER, K. et al., "Thioredoxin reductase as a pathophysiological factor and drug target", Eur. J. Biochem., 267(20):6118-6125 (2000).	
	50.	BERG, D. et al., "14-3-3 Proteins in the nervous system", Nature Reviews Neuroscience, 4:752-62 (2003).	
	51.	BRITTON, R. et al., "New okadaic acid analogues from the marine sponge Merriamum oxeato and their effect on mitosis", J. Nat. Prod., 66:838-43 (2003).	
	52.	CHANG, W-T. et al., "Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway", <i>The Journal of Biological Chemistry</i> ", <u>276</u> (3):2221-2227 (2001).	
	53.	CHEN et al., "Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model", <i>Transplantation</i> , 73(1):115-121 (2002).	
	54.	CHEN et al., "Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion", <i>Transplantation</i> , 70(10):1442-1447 (2000).	
	55.	CHENG et al., "Research on extraction technology of Tripterygium", Chinese Journal of Pharmaceuticals, 21(10):435-436 (No English translation) (1990).	
	56.	CHENG, X.X. et al., Yao Xue Xue Bao, ACTA Pharmaceutica Sinica, 37:339-342 (2002) (English Abstract translation).	1
	57.	DE QUAN Yu et al., "Chemical Transformation of Triptolide", Chinese Chemical Letters, 2(12):937-940 (1991).	
	58.	ENGLEBIENNE et al., <u>Drug Design Reviews -Online</u> , "The Place of Biosteric Sila Substitution in Drug Design", 2 pages (2005).	
- 20	59.	FIDLER, J.M. et al., "PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy", <i>Molecular Cancer Therapeutics</i> , 2(9):855-62 (2003).	
	60.	FIDLER, J.M. et al., "Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. III. Suppression of graft-versus-host disease in murine allogeneic bone marrow transplantation by the PG27 extract", <i>Transplantation</i> , 74(4):445-457 (2002).	
\\ \\	61.	FRUMAN, D.A. et al., "Phosphoinositide Kinases", Ann. Rev. Biochem., 67:481-507 (1998).	Ī
/N.C	62.	FU et al., "14-3-3 Proteins: Structure, Function, and regulation", Ann. Rev. Pharmacol. Toxicol., 40:617-47 (2000).	Ī
EXAMINER		/Nizal Chandrakumar/ DATE CONSIDERED 09/06/2009	
*EXAMINE		ial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in informance and not considered. Include copy of this form with next communication to application(s).	1

		—					COMPLETE IF KNOWN	1
	•					Application Number	10/591,358	t
				DISCLOSURE		Confirmation Number	9546	1
				BY APPLICANT		Filing Date	August 12, 2008	1
			Form PTO-14			First Named Inventor	Yuan et al.	1
		(l	Jse several she	ets if necessary	)	Group Art Unit	1625	1
						Examiner Name	Chandrakumar, Nizal S.	1
_	Shee	t	4	of	9	Attorney Docket No.	57070-8021.US00	1
								,
1	/N	.63.	Journal of I	Pathology, 20	0:500-503 (2	2003).	nd fibrocontractive diseases",	
		64.	players in a	poptosis", Bi	ochimie, <u>85</u> :7	21-726 (2003).	ases PP1 and PP2A are key	
		65.	cells", Cano	er Research	, <u>63</u> (10):2658	3-2664 (2003).	-catenin in human breast cancer	
		66.	spectrum o	f immunologi	cal diseases'	', Immunology_To	clues to the etiopathology of a oday, 5(11):324-332 (1984).	
		67.	signaling in renal fibros	renal tubuloi is; possible r	interstitial cel	ls of hereditary n	uces acceleration of TGF-beta1 ephrotic ICGN mice with chronic tiation", Cell Tissue Res.,	
-		68.		J. and Hunni	nghake, G.W	/., "Idiopathic pul	monary fibrosis", N. Engl. J. Med.,	_
				<u>-525 (2001).</u>				_
		69.	on glutama	te induced P al of Peking l	C12 cell line	damage and its r	n <i>Wilfordii Hook F</i> Monomer T <sub>10</sub> nechanism", <i>Beijing Da Xue Xue</i> 3 <u>5(</u> 3):252-5 (Jun 2003) (English	1
		70.					ics of proteins involved in of Immunology, 175(4):2449-2458	
		71.	and nuclea 8018 (2001	r factor-kapp ).	aB activation	in gastric cancer	olide-induced apoptosis and AP-1 cells", <i>Oncogene</i> , <u>20</u> (55):8009-	
		72.					ycation, diabetic nephropathy, try and Biophysics, <u>419</u> (1):55-62	
		73.	antifertility		of <i>Tripterygiu</i>	m Wilfordii", ACT	ory, immunosuppressive and A Academiae Medicinae Sinicae	1
		74.					n L-plastin in the regulation of 4, <u>95</u> (16):9331-9336 (1998).	
		75.	review", An	nals of. Hepa	tology, <u>2</u> (4):	159-163 (2003).	prosis and inflammation. A	
		76.	KEYSER, F Rgeumatol	. D. et al., "T ogy, <u>14</u> (Supp	he role of T of 1 2):5-9 (199	cells in Rheumato 5).	oid Arthritis", <i>Clinical</i>	
_	<b>V</b> <sub>N.</sub>		KHANNA, A	A.K. and MEI s: potential o	НТА, M.R., "Т	argeted in vitro a tion of allo-immu	nd in vivo gene transfer into T ne activation", <i>BMC Immunology</i> ,	
EXA	MINEF	₹	/Niz	al Chandrakum	ar/	DATE CONSIDERED		
			, 1 412.1	a. onanananum		I	00/06/2000	1

09/06/2009

"EXAMINER: Initial if reference considered, where or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

١.					COMPLETE IF KNOWN	
•				Application Number	10/591,358	
		DISCLOSURE		Confirmation Number	9546	
		BY APPLICANT		Filing Date	August 12, 2008	
	Form PTO-14			First Named Inventor	Yuan et al.	
(	Use several she	ets if necessary	)	Group Art Unit	1625	
				Examiner Name	Chandrakumar, Nizal S.	
Sheet	- 5	of	9	Attorney Docket No.	57070-8021.US00	

	/N	G8.	KORNGOLD, B. and SPRENT, J. "Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow", J. Exp. Med., 148:1687-98 (1978).	
		79.	KUPCHAN S.M. et al., "Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii", <i>American Chemical Society</i> , <u>94</u> (20):7194-7195 (1972).	
		80.	KURZ, E.U. et al., "Modulation of human DNA topoisomerase Ilalpha function by interaction with 14-3-3epsilon", <i>The Journal of Biological Chemistry</i> , <u>275</u> (18):13948-13954 (2000).	
		81.	KUTNEY, J.P. et al., "Studies with plant cell cultures of the Chinese herbal plant, Tripterygium Wilfordii, Synthesis and biotransformation of diterpene analogues", Heterocycles, 44(1):2-11 (1997).	
		82.	LARRIBERE, L. et al., "PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes", Cell Death and Differentiation, 11(10):1084-1091 (2004).	
		83.	LEONARD, C.T. et al., "PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model", <i>Journal of Heart and Lung Transplantation</i> , 21(12):1314-1318 (2002).	
		84.	LEUENROTH, S.J. and CREWS, C.M., "Studies on calcium dependence reveal multiple modes of action for triptolide", <i>Chemistry and Biology</i> , <u>12</u> (12):1259-1268 (2005).	
		85.	LI, K.K. and FIDLER, J.M., "PG490-88 erxerts 1-16 potent anticancer activity alone and in combination therapy in a nude mouse xenograft model", Proceedings of the American Association for Cancer Research Annual Meeting March 2001, 42:73, Abstract #391 (2001)	
		86.	LI, F-Q. et al., "Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons", Experimental Neurology, 179(1):28-37 (2003).	
		87.	LI, F-Q. et al., "Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation", Journal of Neuroimmunology, 148(1-2):24-31 (2004).	
		88.	LIN, C.S. et al., "Upregulation of L-plastin gene by testosterone in breast and prostate cancer cells: identification of three cooperative androgen receptor-binding sequences", DNA Cell Biology, 19(1):1-7 (2000).	
		89.	LIST, A.F. et al., "Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.", Experimental Hematology, 32(6):526-535 (2004).	
1	$V_{/N}$	<u>9</u> 0.	LOVELL, M.A. et al. "Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain", Free Radical Biology & Medicine, 28(3):418-27 (2000).	

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include copy of this form	onformance with MPEP 609. Draw line through citation if not in with next communication to application(s).

, ,			****		COMPLETE IF KNOWN
•				Application Number	10/591,358
	INFORMATION			Confirmation Number	9546
	STATEMENT BY APPLICANT				August 12, 2008
	Form PTO-14			First Named Inventor	Yuan et al.
	(Use several sheets if necessary)				1625
				Examiner Name	Chandrakumar, Nizal S.
Sheet	6	of	9	Attorney Docket No.	57070-8021.US00

/N	.0.1.	LUNDSTROM, J. et al., "A Pro to His mutation in active site of thioredoxin increases its disulfide-isomerase activity 10-fold. New refolding systems for reduced or randomly oxidized ribonuclease", <i>The Journal of Biological Chemistry</i> , 267(13):9047-9052 (1992).	
	92.	LUNDY, S.K. et al., "Cells of the synovium in rheumatoid arthritis", Arthritis Research & Therapy, 9(1):1-11 (2007).	
	93.	MASON et al., "Pharmacological therapy fir idiopathic pulmonary fibrosis", Am. J. Respir. Crit. Care Med., 160:1771-1777 (1999).	
	94.	MASTERS, S.C. AND FU, H., "14-3-3 Proteins mediate an essential anti-apoptotic signal", <i>The Journal of Biological Chemistry</i> , <u>276</u> (48):45193-45200 (2001).	
	95.	MATLIN, S.A. et al., "Male antifertility compounds from <i>Tripterygium Wilfordi Hook F."</i> , Contraception, 47:387-400 (1993).	
	96.	MESA, R.A. et al., "In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia", <i>Leukemia</i> , <u>17</u> (5):849-55 (2003).	
	97.	GU, Ming et al., "Effect of Chinese herb <i>Tripterygium wilfordii</i> Hook F monomer triptolide on apoptosis of PC12 cells induced by Aβ1-42" ACTA Physiologica Sinica, 56(1):73-78 (2004) (English Abstract translation).	1
	98.	MURASE, N. et al., "Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs", <i>Transplantation</i> , <u>55</u> (4):701-708 (1993).	
	99.	NING, L. et al., "Biotransformation of triptolide by Cunninghamella blakesleana", Tetrahedron, <u>59</u> (23):4209-4213 (2003).	
	100	ONO, K. and LINDSEY, E.S., "Improved technique of heart transplantation in rats", Journal of Thoracic and Cardiovascular Surgery, 57(2):225-29 (1969).	
	101	ORY, S. et al., "Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites", <i>Current Biology</i> , 13(16):1356-1364 (2003).	
	102	cancer progression and metastasis", <i>Biochemical and Biophysical Research</i> Communications, 289(4):876-881 (2001).	
	103	PEI, J-J. et al. "Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease", American Journal of Pathology, 163(3):845-858 (2003).	
		POWIS, G. and MONTFORT, W.R., "Properties and biological activities of thioredoxins", <i>Ann.Rev. Pharmacol. Toxicol.</i> , 41:261-295 (2000).	
<b>√</b> N.C	/105	QIU, D. AND KAO, P.N., "Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb <i>Tripterygium wilfordii</i> Hook. f.*, <i>Drugs R&amp;D</i> , 4(1):1-18 (2003).	

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance and not considered. Include conv. of this form	pnformance with MPEP 609. Draw line through citation if not in

					COMPLETE IF KNOWN	
				Application Number	10/591,358	
	INFORMATION			Confirmation Number	9546	
	STATEMENT E			Filing Date	August 12, 2008	
		149 (Modified)		First Named Inventor	Yuan et al.	
	(Use several she	ets if necessary	')	Group Art Unit	1625	
				Examiner Name	Chandrakumar, Nizal S.	
Sheet	7	of	9	Attorney Docket No.	57070-8021.US00	$\neg$

/N.0	S./	QIU, D. et al., "Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation", <i>The Journal of Biological Chemistry</i> , <u>274</u> (19):13443-13450 (1999).	
		REDPATH, N.T. et al., "Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway", <i>The EMBO Journal</i> , <u>15</u> (9):2291-2297 (1996).	
		REICHERT, T.E. et al., "Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression", <i>Oncogene</i> , 19(4):514-525 (2000).	
		SATO, S. et al., "Modulation of Akt kinase activity by binding to Hsp90 ", Proc Natl Acad Sci USA, 97(20):10832-10837 (2000).	
		SCHLESINGER, C. et al., "Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature", <i>Annals of Diagnostics Pathology</i> , <u>2</u> (5):321-34 (1998).	
		SCHLESINGER, C. et al., "Constrictive (obliterative) bronchiolitis ", Current Opinion in Pulmonary Medicine, ≰:288-293 (1998).	
		SCHWALLER, M. et al., "Reduction-reoxidation cycles contribute to catalysis of disulfide isomerization by protein-disulfide isomerase", <i>The Journal of Biological Chemistry</i> , 278(9):7154-7159 (2003).	
	,	SELMAN, M. <i>et al.</i> , "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy ", <i>Ann. Intern. Med.</i> , <u>134</u> :136-151 (2001).	
	114	SHAMON, L.A. et al., "Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from <i>Tripterygium wilfordii</i> ", <i>Cancer Letters</i> , 112:113-117 (1997).	
		SHANMUGANATHAN et al., "Enhanced brain delivery of an anti-HIV nucleoside 2'-F- ara-ddl by xanthine oxidase mediated biotransformation", <i>J. Med. Chem.</i> , <u>37</u> :821-827 (1994).	
		SHEVCHENKO, A. et al., "Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels", Anal. Chem., 68(5):850-858 (1996).	
		SHEVCHENKO, A. et al., "Linking genome and proteome by mass spectrometry: large- scale identification of yeast proteins from two dimensional gels", <i>Proc Natl Acad Sci</i> USA, <u>93</u> :14440-14445 (1996).	
/_		SHOW, M. et al., "Reduced intratesticular testosterone concentration alters the polymerization state of the Sertoli cell intermediate filament cytoskeleton by degradation of vimentin", Endocrinology, 144(12):5530-6 (2003).	
 /N	C1/19	SOLIT, D. et al., "Hsp90 as a therapeutic target in prostate cancer", Seminars in Oncology, 30(5):709-16 (2003).	

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

				C	COMPLETE IF KNOWN
•				Application Number	10/591,358
	INFORMATION			Confirmation Number	9546
	STATEMENT E			Filing Date	August 12, 2008
	Form PTO-14			First Named Inventor	Yuan et al.
	(Use several she	ets if necessary	)	Group Art Unit	1625
				Examiner Name	Chandrakumar, Nizal S.
Sheet	8	of	9	Attomey Docket No.	57070-8021.US00

	SONTAG et al., "Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation", The EMBO Journal, 16(18):5662-5671 (1997).	
'-'	STELLA, V.J. et al., "Prodrugs, Do they have advantages in Clinical Practice?", <i>Drugs</i> , 29:455-473 (1985).	
	TOLSTONOG et al., "Role of the intermediate filament protein vimentin in delaying senescence and in the spontaneous immortalization of mouse embryo fibroblasts", DNA and Cell Biology, 20(9):509-29(2001).	
123	VAN TAMELEN et al., "Biogenetic-type total synthesis of (t, -) -triptonide and (.+) -triptolide", STN International Database, CAPLUS database Document No. 96:143107 2 pages (1982).	
	VIERLING et al., "Highly fluorinated amphiphiles as drug and gene carrier and delivery systems", <i>Journal of Fluorine Chemistry</i> , <u>107</u> :337-354 (2001).	
	WALLER, D.G. and GEORGE, C.F., "Prodrugs", <i>Br. J. Clin. Pharmac.</i> , <u>28</u> :497-507 (1989).	
126	WAHLGREN, C-F. et al, "Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects", <i>Arch Dermatol Res.</i> , 287(6):572-580 (1995).	
	WANG, Z. et al., "Altered distribution of Sertoli cell vimentin and increased apoptosis in cryptorchid rats", Journal of Pediatric Surgery, 37(4):648-652 (2002).	
	WANG, J. et al., "Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. I. Prolongation of rat cardiac and renal allograft survival by the PG27 extract and immunosuppressive synergy in combination therapy with cyclosporine", Transplantation, 70(3):447-455 (2000).	
129	WANG, J. and Morris, R.E., "Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival", <i>Transplantation Proceedings</i> , 23(1):699-702 (1991).	
130	WANG, X. et al., "Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide", <i>J. Mol. Med.</i> , 84:405-415 (2006).	
131	Chinese Traditional and Herbal Drugs, 33(11):1053-1054 (2002) (No English Abstract Translation).	
	WHITESELL, L. et al., "The stress response: implications for the clinical development of hsp90 inhibitors", Current Cancer Drug Targets, 3(5):349-358 (2003).	
133 /N.C./	YAMAGISHI, S. et al., "Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells", Kidney International, 63(2):464-473 (2003).	

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009
*EXAMINER:	Initial if reference considered, whether or not criteria is in co conformance and not considered. Include copy of this form	informance with MPEP 609. Draw line through citation if not in with next communication to application(s).

		_		(	COMPLETE IF KNOWN
				Application Number	10/591,358
	INFORMATION			Confirmation Number	9546
STATEMENT BY APPLICANT				Filing Date	August 12, 2008
		149 (Modified)		First Named Inventor	Yuan et al.
	(Use several sheets if necessary)				1625
				Examiner Name	Chandrakumar, Nizai S.
Sheet	9	of	9	Attorney Docket No.	57070-8021.US00

134 VAMAMOTO, R. et al., "Pharmaceutical Studies on water-Soluble corticosteroid derivatives I. Stability of Hydrocortisone 21 Hemiesters in Solution", Journal of the Pharmaceutical Society of Japan, 46(8):855-862 (1971).  135 VANG, S. et al., "Triptolide Induces apoptotic death of T lymphocyte", Immunopharmacology, 40:139-149 (1998).  136 Vang, J. et al., "Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin", Cancer Research, 61(10):4010-4016 (2001).  137 VANG, S. et al., "Triptolide Inhibits the Growth and Metastasis of Solid Tumors", Molecular Cancer Therapeutics, 2:65-72 (2003).  138 YANO, H. et al., "Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells", The Journal of Biological Chemistry, 268(34):25846-25856 (1993).  139 YUAN, G-H. et al., "Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis", OsteoArthritis and Cartilage, 12(1):38-45 (2004).  140 ZHANG et al., "Studies on Diterpenoids from leaves of Tripterygium Wilfordii", ACTA Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).					
Immunopharmacology, 40:139-149 (1998).		/N.C		derivatives I. Stability of Hydrocortisone 21 Hemiesters in Solution", Journal of the	
mechanism to inhibit glioblastoma by geldanamycin", Cancer Research, 61(10):4010-4016 (2001).  137 YANG, S. et al., "Triptolide Inhibits the Growth and Metastasis of Solid Tumors", Molecular Cancer Therapeutics, 2:65-72 (2003).  138 YANO, H. et al., "Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells", The Journal of Biological Chemistry, 268(34):25846-25856 (1993).  139 YUAN, G-H. et al., "Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis", OsteoArthritis and Cartilage, 12(1):38-45 (2004).  140 ZHANG et al., "Studies on Diterpenoids from leaves of Tripterygium Wilfordii", ACTA Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			135		
Molecular Cancer Therapeutics, 2:65-72 (2003).  YANO, H. et al., "Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells", The Journal of Biological Chemistry, 268(34):25846-25856 (1993).  139 YUAN, G-H. et al., "Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis", OsteoArthritis and Cartilage, 12(1):38-45 (2004).  140 ZHANG et al., "Studies on Diterpenoids from leaves of Tripterygium Wilfordii", ACTA Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			136	mechanism to inhibit glioblastoma by geldanamycin", Cancer Research, 61(10):4010-	
of phosphatidylinositol 3-kinase in RBL-2H3 cells", <i>The Journal of Biological Chemistry</i> , 268(34):25846-25856 (1993).  139 YUAN, G-H. <i>et al.</i> , "Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis", <i>OsteoArthritis and Cartilage</i> , 12(1):38-45 (2004).  140 ZHANG et al., "Studies on Diterpenoids from leaves of <i>Tripterygium Wilfordii</i> ", ACTA Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. <i>et al.</i> , "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", <i>Neuroreport</i> , 14(7):1091-5 (2003).	Г		137		
cartilage of advanced osteoarthritis", OsteoArthritis and Cartilage, 12(1):38-45 (2004).  140 ZHANG et al., "Studies on Diterpenoids from leaves of Tripterygium Wilfordii", ACTA Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			138	of phosphatidylinositol 3-kinase in RBL-2H3 cells", The Journal of Biological Chemistry,	
Pharmaceutica Sinica, 28(2):110-115 (1993). (English Abstract translation)  141 ZHENG et al., "Screening of active iantiinflammatory, immunosuppressive and antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			139		
antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract No. 83085a (1992)  142 ZHOU, H-F. et al., "Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			140		1
primary microglial cultures", Neuroreport, 14(7):1091-5 (2003).			141	antifertility components of Tripterygium Wilfordii", Chemiacl Abstracts 117(9): Abstract	
N.Cl/143 ZHOU, Y.X. et al., Ai Zheng 21:1108-8 (2002).	\	,	142		
		/N.C	/143	ZHOU, Y.X. et al., Ai Zheng <u>21</u> :1108-8 (2002).	

EXAMINER	/Nizal Chandrakumar/	DATE CONSIDERED 09/06/2009
*EXAMINER	: Initial if reference considered, whether or not criteria is in c	onformance with MPEP 609. Draw line through citation if not in